1/Reading the FDA report of Pfizer Vax EUA. Some interesting points

https://www.fda.gov/media/144245/download

2/It says “In the event an EUA is issued for this product, it would still be considered unapproved and it would be under further investigation until it is licensed under a Biologics License Application (BLA). Study will be completed January 2023

3/ The Vax group 14.4% had evidence of infection within 7 days of their 2nd shot. 15% in placebo group.

Following 7 days after last shot, Only 0.05% COVID IN VAX GROUP. 1% dev COVID in placebo group over next 2 months. Why the drop in infection rate in placebo

4/ Antibody test was used to confirm covid after 7 days following the 2nd shot. Why not use PCR test on everyone like they are doing in the real world? Too many false positives? However PCR was done within 7 days of the final shot and not the Antibody Test. this makes sense?

5/ only 1 severe COVID was found in the VAX group. A whopping 3 in the placebo group (each group had over 20,000 participants). Sounds like a disease in which no vaccine is needed.

6/ there were 4 cases of Bells Palsy in the Vax group (none in placebo group) within 2 months. In the population there are 15–30 cases per 100,000 population annual incidence. Thats 4-10 times higher incidence of Bells Palsy in the group as they were followed for only 2 months

7/ As specified in the protocol, suspected cases of symptomatic COVID-19 that were not PCR confirmed were not recorded as adverse events unless they met regulatory criteria for seriousness.
So adverse effects may have been blamed on SUSPECTED COVID (not confirmed) instead of vax

8/PCR-Ct not specified

9/Providers administering the Vaccine must report to VAERS and to Pfizer the information all adverse events associated with the vaccine :

Are Walmart and pharmacies able to do so? This is normally done by Doctors

10/An additional source of VAERS reports will be through a new smartphone-based App named V-safe. It uses text messaging and web surveys from CDC to check w/vaccine recipients for health problems following COVID-19 vaccination. The system also will provide telephone follow-up

11/available data are insufficient to make conclusions about benefit in individuals with prior SARS-CoV-2 infection.

12/Data are limited to assess the effect of the vaccine against asymptomatic infection . Additional evaluations will be needed

13/ COVID-19 disease may have long-term effects on certain organs, and at present it is not possible to assess whether the vaccine will have an impact on specific long-term sequelae of COVID-19 disease in individuals who are infected despite vaccination.

14/ A larger number of individuals at high risk of COVID-19 and higher attack rates would be needed to confirm efficacy of the vaccine against mortality.

15/ Data are limited to assess the effect of the vaccine against transmission of SARS-CoV-2 from individuals who are infected despite vaccination.. asymptomatic cases in combination with reduced mask-wearing and social distancing could result in significant continued transmission

16/There are currently insufficient data to make conclusions about the safety of the vaccine in subpopulations such as children less than 16 years of age, pregnant and lactating individuals, and immunocompromised individuals.

17/.. [the]risk of vaccine-enhanced disease over time, potentially associated with waning immunity, remains unknown and needs to be evaluated further in ongoing clinical trials and in observational studies that could be conducted following authorization and/or licensure